Introducing STEQEYMA: A New Era for Biosimilars in the U.S.
Transforming Patient Care with STEQEYMA
Celltrion is proud to announce a landmark development in the world of biologics: the launch of STEQEYMA (ustekinumab-stba), a pioneering biosimilar to STELARA (ustekinumab). This exciting new drug is now available in the United States, expanding treatment options for patients suffering from chronic inflammatory conditions.
Enhancing Accessibility to Treatment
STEQEYMA has received approval from the FDA for the same indications as STELARA, making it a reliable alternative for many patients. With the goal of increasing access to effective treatment, STEQEYMA is priced at an impressive 85% discount compared to the current wholesale acquisition cost of STELARA. This new pricing strategy is aimed at improving affordability for patients, enabling them to access a high quality of care without the burden of excessive costs.
Comprehensive Immunology Portfolio
By introducing STEQEYMA into its arsenal, Celltrion is significantly expanding its offerings beyond traditional tumor necrosis factor (TNF) inhibitors. STEQEYMA serves as an interleukin (IL)-12 and IL-23 inhibitor, thereby broadening the spectrum of treatment options available for diverse immune-mediated diseases. This is a crucial step toward addressing the needs of patients dealing with conditions like plaque psoriasis (PsO), psoriatic arthritis (PsA), Crohn's disease (CD), and ulcerative colitis (UC).
Supporting Patients on Their Journey
Celltrion understands that navigating treatment options can be overwhelming for patients. That's why the company provides robust support through the Celltrion CONNECT Patient Support Program, which offers assistance throughout the treatment journey. This program is designed to facilitate benefits verification, prior authorization help, and co-pay assistance, ensuring patients receive the care they need without financial strain. Eligible individuals may even pay as little as $0 out-of-pocket per dose, making essential treatments much more attainable.
Focus on Safety and Effectiveness
The approval of STEQEYMA wasn't given lightly; it was granted after thorough examination and robust data supporting its safety and effectiveness, including the results from a Phase III clinical trial. Patients experienced clinically significant improvements without meaningful differences in safety compared to the reference biologic, ustekinumab. This gives healthcare providers the confidence they need to prescribe this new option to their patients.
Expanding Global Reach
While STEQEYMA is making a significant impact in the U.S., it has also gained approval in various international markets, including the European Union and Australia. This global footprint ensures that patients around the world can benefit from this innovative treatment and its cost-saving potential.
About Celltrion's Commitment
Celltrion is not just a name in the biopharmaceutical industry; it is a leader dedicated to finding novel solutions that enhance the quality of life for individuals living with chronic illnesses. By expanding its biosimilar portfolio and focusing on patient-centered initiatives, Celltrion positions itself as a key player in the ongoing battle against immune-mediated diseases.
Stay Informed and Connected
For the latest updates and access to resources regarding STEQEYMA and other offerings, patients and healthcare providers are encouraged to visit Celltrion’s dedicated websites and social media channels. This proactive communication is essential for staying informed about advancements in treatment options and support services available to patients.
Frequently Asked Questions
What is STEQEYMA?
STEQEYMA is a biosimilar to STELARA, specifically designed for treating chronic inflammatory diseases like plaque psoriasis and psoriatic arthritis.
How does STEQEYMA improve patient access to treatment?
It offers an 85% reduction in pricing compared to STELARA, making it more affordable for patients seeking high-quality biologic therapies.
What are the indications for STEQEYMA?
Approved indications include plaque psoriasis and psoriatic arthritis in both pediatric and adult patients, as well as Crohn's disease and ulcerative colitis in adults.
What support does Celltrion offer for patients using STEQEYMA?
Celltrion provides extensive assistance through programs like Celltrion CONNECT, which includes co-pay assistance and treatment support.
Is STEQEYMA available globally?
Yes, STEQEYMA has received approvals in several regions, including the European Union and Australia, following its U.S. launch.
About The Author
Contact Kelly Martin privately here. Or send an email with ATTN: Kelly Martin as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.